IBD Drug Company Debuts with $180M
Summary
cAMPfield Therapeutics launched with $180 million in Series A funding and an oral inflammatory bowel disease drug candidate called prifemilast. The company licensed the drug from Newsoara Biopharma and plans global clinical development outside greater China. It will start Phase 2b trials for ulcerative colitis and Phase 2 trials for Crohn’s disease. The founding team brings deep experience from major biopharma companies, which helped attract investor confidence quickly.
Funding
Amount
$180.0M
Total raised
Date
June 30, 2026
Announcement date
Investors
-
Lead investors
Company
campfieldtx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected